Providence Holy Cross Medical Center is the first Providence hospital in the San Fernando Valley to offer a minimally ...
Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...
New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.
After 1 year of biologic therapy, admissions requiring noninvasive ventilation among patients with COPD and type 2 ...
TipRanks on MSN
Sanofi’s New COPD Treatment Study: A Potential Game-Changer?
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...
Due to chronic inflammation, those with COPD must learn to listen to what their bodies are telling them, writes columnist.
Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion ...
Labored breathing could be a sign of an underlying health condition like heart failure, COPD, or a pulmonary embolism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback